OPEN END TURBO OPTIONSSCHEIN SHORT - ASTRAZENECA | Market Closed - BOERSE MUENCHEN 19:27:19 31/05/2024 BST | ||
| 1.19 EUR | -12.50% |
|
| Current month | -13.14% | ||
| 1 month | -13.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.19 | -12.50% |
| 30/05/24 | 1.36 | -6.21% |
| 29/05/24 | 1.45 | +1.40% |
| 28/05/24 | 1.43 | +39.65% |
| 27/05/24 | 1.024 | -1.06% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 07:27 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GG64L2 |
| ISIN | DE000GG64L22 |
| Date issued | 12/04/2024 |
| Strike | 13,191 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.768 € |
|---|---|
| Lowest since issue | 0.887 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
